(vianews) - sanofi (san.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| sanofi (san.pa) | €88.73 | 4.26% | 7.27% |
| tubize-fin (tub.br) | €92.90 | 1.03% | 4.93% |
| vetoquinol (veto.pa) | €98.70 | 1.02% | 12.13% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. sanofi (san.pa)
4.26% forward dividend yield and 7.27% return on equity
sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the united states, europe, and internationally. it operates through pharmaceuticals, vaccines, and consumer healthcare segments. the company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. in addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis a, typhoid, cholera, yellow fever, and rabies vaccines. the company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. further, it has a collaboration and license agreement with exscientia to develop up to 15 novel small-molecule for oncology and immunology; abl bio, inc. to develop abl301, a treatment for alpha-synucleinopathies; blackstone life sciences to develop pivotal studies and clinical development program; and seagen inc. to design, develop, and commercialize antibody-drug conjugates for cancer. additionally, the company has a collaboration agreement with igm biosciences, inc. to develop, manufacture, and commercialize igm antibody; skyhawk therapeutics, inc to discover and develop novel small molecules; and adagene inc., for the discovery and development of antibody-based therapies. it also has collaborations with scribe therapeutics inc. to develop genome editing technologies; and co-promotion service agreement with provention bio, inc. for the commercialization of teplizumab. the company was formerly known as sanofi-aventis and changed its name to sanofi in may 2011. sanofi was founded in 1973 and is headquartered in paris, france.
earnings per share
as for profitability, sanofi has a trailing twelve months eps of €4.3.
pe ratio
sanofi has a trailing twelve months price to earnings ratio of 20.63. meaning, the purchaser of the share is investing €20.63 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.27%.
revenue growth
year-on-year quarterly revenue growth grew by 2.9%, now sitting on 46.03b for the twelve trailing months.
growth estimates quarters
the company's growth estimates for the current quarter and the next is a negative 18.5% and a negative 6.3%, respectively.earnings before interest, taxes, depreciation, and amortization
sanofi's ebitda is 2.57.
more news about sanofi.
2. tubize-fin (tub.br)
1.03% forward dividend yield and 4.93% return on equity
financière de tubize sa operates as a mono holding company whose sole investment is a stake in ucb which is a biopharma company in belgium. the company is based in brussels, belgium.
earnings per share
as for profitability, tubize-fin has a trailing twelve months eps of €1.98.
pe ratio
tubize-fin has a trailing twelve months price to earnings ratio of 46.92. meaning, the purchaser of the share is investing €46.92 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.93%.
yearly top and bottom value
tubize-fin's stock is valued at €92.90 at 16:30 est, above its 52-week high of €88.60.
dividend yield
as claimed by morningstar, inc., the next dividend payment is on may 3, 2023, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 1.03%.
volatility
tubize-fin's last week, last month's, and last quarter's current intraday variation average was 2.39%, 0.77%, and 1.41%.
tubize-fin's highest amplitude of average volatility was 2.96% (last week), 2.01% (last month), and 1.41% (last quarter).
volume
today's last reported volume for tubize-fin is 20771 which is 53.26% above its average volume of 13552.
more news about tubize-fin.
3. vetoquinol (veto.pa)
1.02% forward dividend yield and 12.13% return on equity
vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.
earnings per share
as for profitability, vetoquinol has a trailing twelve months eps of €4.97.
pe ratio
vetoquinol has a trailing twelve months price to earnings ratio of 19.86. meaning, the purchaser of the share is investing €19.86 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.13%.
more news about vetoquinol.